Treatment of Metastatic Cancer in Terminally Diagnosed Patients
ConditionMetastatic Cancer
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
AgeNot listed
SponsorMatrix Biomed, Inc.
About this trial
The objective is to provide terminally diagnosed patients with a last line of treatment while improving overall quality of life. Tempol can be added to any chemotherapy regimen to potentially reduce side effects and overcome chemoresistance.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
metastatic terminally diagnosed cancer
Disqualifiers
None
Trial design
Treatments tested in this trial
Tempol
DrugTempol will be given as an adjunct to chemotherapy.
Treatment groups
No treatment groups listed
Trial outcomes
This trial has no outcomes listed.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov